title: Role of L-lysine HCl in adoptive immune therapy towards development of suitable tuberculosis vaccination.
abstract: L-Lysine HCI is being proposed to be a possible biocompatible adjuvant to enhance immune response by virtue of its probable non-specific bridging action and cellular proliferation properties. This proposal has been tried to be substantiated by designing an in vitro culture protocol, varying the concentration of L-lysine HCI and its further in vivo application. Splenic lymphocyte population has been extracted from mice and co-cultured with extracted mice macrophage population in presence of either Bacille Calmette Guerrin (BCG) or Hepatitis B surface antigen (HbsAg) and added L-lysine hydrochloride in culture media. Post incubation of these cultures, "taught" cell population has been adoptively transferred in naïve mice. These mice were then challenged by respective antigen dose, Change in Immune response with this challenge was noted. Antibody titre was followed in all the experiments as a measure of immune response. In adoptive immune transfer experiment of with HbsAg (AIT-HbsAg), similar to that with BCG (AIT-BCG), after the incubation period, antibody titre was higher in added lysine containing cultures in comparison with the control ones. Post transfer followed by antigen challenge, in AIT-BCG the expected augmentation in immune response was hardly visible. But in AIT-HbsAg, with the help of lysine booster, the animals responded better as far as the antibody titre is concerned.
authors.affiliation: Cellular Engineering Laboratory, BJM School of Biosciences and Bioengineering, Indian Institute of Technology, Mumbai 400 076, India.
authors.forename: S
authors.initials: S
authors.lastname: Dasgupta
authors.forename: V
authors.initials: V
authors.lastname: Chandran
authors.forename: A
authors.initials: A
authors.lastname: Bhinge
authors.forename: S
authors.initials: S
authors.lastname: Sewlikar
authors.forename: A
authors.initials: A
authors.lastname: Nimbkar
authors.forename: D
authors.initials: D
authors.lastname: Datta
mesh_terms: D000818:Animals; D001500:BCG Vaccine / Q000008:administration & dosage; D005260:Female; D017325:Hepatitis B Vaccines / Q000008:administration & dosage; D007155:Immunologic Factors / Q000008:administration & dosage; D016219:Immunotherapy, Adoptive; D066298:In Vitro Techniques; D008239:Lysine / Q000008:administration & dosage*; D051379:Mice; D008807:Mice, Inbred BALB C; D032581:Tuberculosis Vaccines / Q000008:administration & dosage*
chemical_list: D001500:BCG Vaccine; D017325:Hepatitis B Vaccines; D007155:Immunologic Factors; D032581:Tuberculosis Vaccines; D008239:Lysine